Potential access disparities for Moderna-Merck cancer vaccines in European markets

Moderna and Merck's recent cancer vaccine breakthrough faces potential distribution hurdles in Europe due to pricing and regulatory negotiations. It remains uncertain whether European health systems will secure access to these therapies at current price points, highlighting ongoing tensions between pharmaceutical innovation costs and public healthcare budget constraints.